Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

11.71
-0.6600-5.34%
Post-market: 11.800.0900+0.77%18:48 EDT
Volume:8.29M
Turnover:98.90M
Market Cap:1.64B
PE:-3.50
High:12.41
Open:12.08
Low:11.70
Close:12.37
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.37
T/O Rate:6.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.25
PE(LYR):-3.07

Loading ...

Lineage Cell Therapeutics Q2 Revenue Falls but Posts Profit

Reuters
·
Aug 07

Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating

MT Newswires Live
·
Aug 06

Intellia Therapeutics, INC. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Earnings Flash (NTLA) Intellia Therapeutics Posts Q2 Loss $0.80 a Share, vs. FactSet Est of $0.80 Loss

MT Newswires Live
·
Aug 06

Intellia Therapeutics reports Q2 EPS (80c), consensus (78c)

TIPRANKS
·
Aug 06

Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens

Reuters
·
Aug 06

Intellia Q2 FY26 Net Loss Widens to $106.63 Million; Revenue Falls to $7.66 Million

Reuters
·
Aug 06

Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M Estimate

Benzinga Earnings
·
Aug 06

Intellia Therapeutics Q2 Net Income USD -106.634 Million

Reuters
·
Aug 06

Intellia Therapeutics Q2 Basic EPS USD -0.8

THOMSON REUTERS
·
Aug 06

Intellia Therapeutics (NTLA) Stock Looks Overvalued On Sales But Fairer On Broader Checks

Simply Wall St.
·
Aug 06

Intellia Therapeutics Schedules Conference Call to Discuss Q2 2026 Results and Business Updates

Reuters
·
Jul 30

Intellia Therapeutics Cut to Underperform from Peer Perform by Wolfe Research

Dow Jones
·
Jul 16

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Jul 16

Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research

TIPRANKS
·
Jul 16

Movement Alert|Intellia Therapeutics Falls 9.74% in Regular Trading, Trading at $12.84

Market Focus
·
Jul 14

Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch Plans - What's Changed

Simply Wall St.
·
Jul 11

Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

TIPRANKS
·
Jul 10

Intellia Therapeutics is Maintained at Neutral by Wedbush

Dow Jones
·
Jul 10

Wedbush Raises Intellia Therapeutics Price Target to $17 From $12, Maintains Neutral Rating

MT Newswires Live
·
Jul 10